XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
I
I

Incyte


Actualités

Incyte's blood cancer drug succeeds late-stage trial

Incyte's blood cancer drug succeeds late-stage trial Aug 15 (Reuters) - Incyte INCY.O said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer. The company said its drug Monjuvi, combined with Bristol Myers Squibb's BMY.N drug, Revlimid, and Biogen's BIIB.O Rituxan achieved progression free survival in patients with follicular lymphoma (FL), when compared to Rituxan and Revlimid alone.
B
G
I
N

Incyte Announces Topline Results From Study Of Tafasitamab (Monjuvi®)

BRIEF-Incyte Announces Topline Results From Study Of Tafasitamab (Monjuvi®) Aug 15 (Reuters) - Incyte Corp INCY.O : INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®) IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA INCYTE: PHASE 3 INMIND TRIAL MET ITS PRIMARY ENDPOINT INCYTE:EXPECTS TO FILE SUPPLEMENTAL BIOLOGICS
I

Syndax rises as FDA approves company's treatment for chronic graft-versus-host disease

BUZZ-Syndax rises as FDA approves company's treatment for chronic graft-versus-host disease ** Shares of Syndax Pharmaceuticals SNDX.O rise 4% to $20.37 in afternoon trade ** The U.S. FDA, late on Wednesday, approved Syndax and partner Incyte's INCY.O drug Niktimvo for patients with chronic graft-versus-host disease (GvHD) ** GvHD is a potentially
I
S

U.S. Allstate, bluebird bio , Vicinity Motor

U.S. RESEARCH ROUNDUP-Allstate, bluebird bio , Vicinity Motor Aug 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Allstate, bluebird bio and Vicinity Motor, on Thursday. HIGHLIGHTS * Allstate Corp ALL.N : CFRA cuts to hold from buy * Autodesk Inc ADSK.O : Baird raises target price to $295 from $289 * bluebird bio Inc BLUE.O : JP Morgan cuts to neutral from overweight * Provident Financial Services Inc PFS.N : KBW
A
A
C
G
I
K
D
A

Incyte, Syndax Get FDA Approval For Niktimvo (axatilimab-csfr)

BRIEF-Incyte, Syndax Get FDA Approval For Niktimvo (axatilimab-csfr) Aug 14 (Reuters) - Incyte Corp INCY.O : INCYTE AND SYNDAX ANNOUNCE U.S. FDA APPROVAL OF NIKTIMVO™ (AXATILIMAB-CSFR) FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) Source text for Eikon: ID:nBw712pWHa Further company coverage: INCY.O
I

FDA approves Incyte's treatment for chronic graft-versus-host disease

UPDATE 2-FDA approves Incyte's treatment for chronic graft-versus-host disease Rewrites throughout, adds analyst comment in paragraph 9 By Christy Santhosh and Sruthi Narasimha Chari Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Incyte's INCY.O treatment for chronic graft-versus-host disease (GvHD), a potentially fatal complication that could occur after a stem cell transplant.
I
S

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals (Aug. 5)

CORRECTED-U.S. RESEARCH ROUNDUP-Booking Holdings, Doordash, Vertex Pharmaceuticals (Aug. 5) Corrects U.S. research roundup dated Aug. 5 to remove dated research actions from headline and tables, the errors appeared in previous versions also Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday.
A
A
B
I
M
P
A
A
E
A
E
I
A
A
A
A
F
G
H
L
L

Incyte Corp reports results for the quarter ended in June - Earnings Summary

Incyte Corp reports results for the quarter ended in June - Earnings Summary Incyte Corp INCY.OQ reported a quarterly adjusted loss of $1.82​​ per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of 99 cents. The mean expectation of twenty two analysts for the quarter was for a loss of $1.55 per share.
I

Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi

Incyte raises lower end of 2024 sales forecast for blood disorder drug Jakafi July 30 (Reuters) - Incyte Corp INCY.O on Tuesday raised the lower end of the annual sales forecast range for its blood disorder drug Jakafi, on the back of strong demand for the treatment, and also reported better-than-expected quarterly revenue of a newer drug. Shares of the company rose 3.4% before the bell.
I
N

Incyte Q2 Adjusted 1.82

BRIEF-Incyte Q2 Adjusted EPS USD -1.82 Jul 30 (Reuters) - Incyte Q2 EPS USD -2.04. Q2 adjusted operating income USD -378.801 million Q2 operating income USD -478.13 million Q2 revenue USD 1,043.759 million
I

Microsoft and job openings to hit pre-Fed vigil

MORNING BID AMERICAS-Microsoft and job openings to hit pre-Fed vigil A look at the day ahead in U.S. and global markets from Mike Dolan To the extent that worries about pricey tech stocks and rising AI capex spending were partly behind last week's market shakeout, Microsoft's quarterly update should prove a key moment later on Tuesday, just as the Federal Reserve's latest policy meeting gets under way.
A
A
E
G
I
M
M
N
P
S
U
A
G
J
U
U
U
F
E
E
S
A
H
L

Incyte Corp <INCY.OQ> expected to post earnings of $1.11 a share - Earnings Preview

Incyte Corp expected to post earnings of $1.11 a share - Earnings Preview Incyte Corp INCY.OQ INCY.O is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The Wilmington Delaware-based company is expected to report a 6.4% increase in revenue to $1.015 billion from $954.61 million a year ago, according to the mean estimate from 18 analysts, based on LSEG data.
I

U.S. Alexander & Baldwin, Instructure Holdings, RPM International

U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International July 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alexander & Baldwin, Instructure Holdings and RPM International, on Friday. HIGHLIGHTS * Alexander & Baldwin Inc (Hawaii) ALEX.N : Piper Sandler raises to overweight from neutral * First Financial Northwest Inc FFNW.O : Piper Sandler cuts to neutral from overweight * Instructure H
C
D
H
I
A
D
E
A
A
C
E
G

U.S. BlackRock, Goldman Sachs, Netflix

U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix July 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BlackRock, Goldman Sachs and Netflix, on Tuesday. HIGHLIGHTS * Ameriprise Financial Inc AMP.N : RBC raises target price to $487 from $480 * BlackRock BLK.N : JP Morgan raises target price to $774 from $756 * Goldman Sachs GS.N : HSBC raises target price to $527 from $493 * Moody's Corp MCO.N : JP Morgan rai
A
A
B
C
G
I
N
A
D
G
S
W
A
P

U.S. STOCKS Helios Technologies, Indivior, Principal Financial

BUZZ-U.S. STOCKS ON THE MOVE-Helios Technologies, Indivior, Principal Financial Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq hovered at record highs on Tuesday, propelled by gains in Nvidia and other megacaps, as U.S.
I
I
N
P
T
C
U
U
S

U.S. STOCKS Tesla, Archer Aviation, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Archer Aviation, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 edged up on Tuesday, boosted by gains in Tesla and megacap stocks, while the Dow was flat with investors assessing Federal Reserve Chairman Jerome Powell's comments on the need for more evidence before cutting rates.
I
P
P
P
P
T
L
O
W
U
U
U

U.S. STOCKS Tesla, Pure Storage, Rivian

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Pure Storage, Rivian Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street indexes traded lower on Tuesday after Federal Reserve Chairman Jerome Powell said more evidence was needed before cutting interest rates, while gains in Tesla shares kept losses in check.
I
P
P
T
L
O
W
U
U
U

U.S. STOCKS PayPal, Paramount Global, Novo Nordisk

BUZZ-U.S. STOCKS ON THE MOVE-PayPal, Paramount Global, Novo Nordisk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street was on track for a lower open on Tuesday as megacap stocks retreated after a strong session, with additional caution creeping in ahead of jobs opening data and comments from Federal Reserve Chairman Jerome Powell later in the day.
I
P
T
U
R

U.S. STOCKS Atlassian, Comerica, Tesla

BUZZ-U.S. STOCKS ON THE MOVE-Atlassian, Comerica, Tesla Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures fell on Tuesday as megacap stocks retreated after a strong session, with additional caution creeping in ahead of jobs opening data and comments from Federal Reserve Chairman Jerome Powell later in the day.
I
T
U
R

Incyte drops after BMO downgrades to 'underperform'

BUZZ-Incyte drops after BMO downgrades to 'underperform' ** Shares of drugmaker Incyte Corp INCY.O down ~3% at $59.01 in premarket trading ** BMO Capital Markets cuts stock to "underperform" from "market perform"; trims PT to $48 from $52 ** Says co's $2 bln Dutch auction has cut capacity to acquire while generating minimal incremental value for sh
I



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques